SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

Enanta Logs Wider 4Q Loss, Lower Revenue on Declining Hepatitis C Treatment Royalties

By Natalie WegerEnanta Pharmaceuticals posted a wider loss and lower revenue in the fourth quarter due to declining royalties tied to an AbbVie hepatitis C virus treatment.Biotechnology company Enanta on Monday reported a loss of $23.7 million, or 81 cents a share, compared with a loss of $18.7 mil…

ENTA

Related stories